Company Reports

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.

For the second quarter, Mettler-Toledo delivered 6% local currency revenue growth and adjusted diluted EPS of $11.46, above FactSet consensus. The firm raised guidance for full-year local currency revenue growth to 4%-5% and adjusted EPS to $47.15-$47.50.

Mettler-Toledo reported 1% year-on-year organic revenue growth in local currencies and adjusted EPS growth of 9%. Management raised full-year guidance for adjusted earnings per share growth to 9% at the midpoint, or 50 basis points higher than February's guidance. Shares are trading down 15%.

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.

Mettler-Toledo delivered 8% local currency revenue growth in the fourth quarter. Management increased 2026 full-year adjusted EPS guidance to $46.05-$46.70 while reaffirming approximately 4% local currency sales growth for the year.

Mettler-Toledo delivered 6% local currency revenue growth in the third quarter. Management increased full-year guidance to reflect approximately 2% local currency sales growth and now expects adjusted EPS in the range of $42.05 to $42.25. Shares are within 1% of the previous market close.

Mettler-Toledo reported a 2% increase in local-currency sales. Management reaffirmed its full-year local currency sales growth outlook of 1%-2% and modestly raised adjusted earnings per share guidance to $41.70-$42.20, after accounting for the impact of revised tariff rates announced yesterday.

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.

Narrow-moat Mettler-Toledo reported first-quarter results that were broadly in line with our expectations. Local currency sales declined 3% year over year but increased 3% when adjusted for the impact of delayed shipments recognized in the prior year. Management highlighted a more uncertain macroeconomic environment and revised its full-year local currency sales growth guidance to 1%-2%, down from the prior 3% growth rate. After updating our model to reflect the more conservative outlook, we lower our fair value estimate to $1200 per share from $1240.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

Narrow-moat Mettler-Toledo reported strong fourth-quarter results that came in slightly higher than our expectations. Local currency sales rose 12%, reaching $1.045 billion, driven by robust demand for laboratory products, particularly in Europe. Following this quarter's performance, management has reiterated its full-year 2025 revenue guidance while increasing the adjusted diluted EPS forecast to a range of $42.35 to $43.00. After updating our model, we increase our fair value estimate to $1,240 per share from $1,200.

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.

Narrow-moat Mettler-Toledo reported solid third-quarter results that were largely in line with our expectations. Local currency sales grew by 1%, driven by strong performance in the laboratory segment, with particularly robust growth in the service business. Following these results, management reiterated its 2024 full-year guidance, projecting sales growth of 2%, and slightly raised its adjusted EPS outlook to a range of $40.35 to $40.50. After making modest adjustments to our near-term forecast, we are maintaining our $1,200 fair value estimate.

Narrow-moat Mettler Toledo reported better than expected second quarter results, despite facing macroeconomic challenges and unfavorable foreign currency pressures. This has translated into the firm reporting adjusted operating profit of $551 million, marking a 4% year-over-year decline but surpassing their prior-quarter forecast. Management’s guidance for the remainder of 2024 remains largely unchanged and aligns closely with our forecasts, leading us to uphold our fair value estimate of $1,200.

We are refreshing our thoughts on Mettler-Toledo and maintaining our narrow moat rating based on its leading market share across product lines and geographies, its high-quality brand name, and modest switching costs inherent in its business. After reevaluating Mettler’s ability to weather market cyclicality and protect both top and bottom lines relatively well in economic downturns, we lowered our cost of capital assumptions to 6.9% from 8.6%, previously. As a result, our fair value estimate rose to $1,200 per share from $880. We view shares as modestly overvalued.

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.

Narrow-moat Mettler-Toledo posted first-quarter results that were better than anticipated, despite the weaker conditions that persisted across the business. The solid start to the year suggests that normalization could be coming soon, and this leads us to maintain our $880 fair value estimate after confirming that our 2024 and longer-term forecasts appear intact. Shares still look overvalued, especially after the stock rose on these strong results.

We are maintaining our $880 fair value estimate for narrow-moat Mettler-Toledo as fourth-quarter and full-year 2023 results were about as expected. Following the January announcement of shipping delays impacting sales late in the fourth quarter, we updated our model to temper our 2023 revenue and adjusted EPS forecasts while lifting our respective 2024 forecasts to reflect the anticipated recovery in sales in first-quarter 2024. Shares currently look overvalued relative to our unchanged valuation.

Mettler-Toledo is the global market leader in laboratory and industrial scales and balances and holds a leading position in product inspection. Apart from its majority share in laboratory balances, the company operates in competitive markets and holds an average share of about 25% across most product lines. While the competitive nature of these markets makes incremental share gains somewhat difficult, Mettler's intense focus on internal sales and marketing initiatives combined with its ongoing efficiency programs have helped the company defy trends in its relatively slow-growing end markets.